Maintenance Mirikizumab Proves Mettle in Ulcerative Colitis

(MedPage Today) -- A maintenance program with mirikizumab offered clinical benefit in patients with moderate-to-severe ulcerative colitis who first responded to induction therapy with the drug, according to the phase III LUCENT-2 trial.
Among...